US Patent 12,291,508: CRM1-Targeted Treatment Method Claims and Scope
What does US 12,291,508 claim? (Claim-by-claim scope)
US 12,291,508 claims a method of treating diseases associated with “CRM1 activity” by administering a pharmaceutical composition that includes a compound with a specified structural formula (the formula is not reproduced in the prompt, so the analysis treats the “compound of the following structural formula” as the defining active moiety). The claims are drafted in a classic method-of-treatment format with broad disease coverage and narrower formulation/combination/route limitations.
Independent claim
| Claim |
Core limitation(s) |
Practical claim scope |
| 1 |
(i) “method for treating a disorder associated with CRM1 activity” and (ii) administering a “therapeutically effective amount” of a pharmaceutical composition comprising “a compound of the following structural formula” plus a pharmaceutically acceptable carrier |
Establishes the baseline: any qualifying subject with a CRM1-associated disorder can be treated with the specified compound/formulation, regardless of route, timing, dosing regimen, or combination therapy (unless limited elsewhere by dependent claims). |
Dependent claims (disease narrowing + combination + oral dosing)
| Claim |
Additional limitation(s) beyond claim 1 |
Incremental scope effect |
| 2 |
disorder is multiple myeloma |
Narrows “disorder associated with CRM1 activity” to MM. |
| 3 |
disorder is a lymphoma |
Narrows to lymphoma (broad subtype coverage unless specification restricts). |
| 4 |
further comprises administering an “effective amount of a second therapeutic agent” |
Adds combination-therapy coverage, but not the identity of the second agent. |
| 5 |
pharmaceutical composition administered orally |
Adds route-of-administration limitation. |
| 6 |
(from claim 2) MM + further second therapeutic agent |
Combination coverage for MM. |
| 7 |
(from claim 2) MM + oral dosing |
Route-specific MM coverage. |
| 8 |
(from claim 3) lymphoma + second therapeutic agent |
Combination coverage for lymphoma. |
| 9 |
(from claim 3) lymphoma + oral dosing |
Route-specific lymphoma coverage. |
| 10 |
disorder is myelodysplastic syndrome (MDS) |
Narrows to MDS. |
| 11 |
(from claim 10) MDS + second therapeutic agent |
Combination coverage for MDS. |
| 12 |
(from claim 10) MDS + oral dosing |
Route-specific MDS coverage. |
| 13 |
disorder is myeloproliferative disorder |
Narrows to MPD (breadth depends on definition in the patent). |
| 14 |
(from claim 13) MPD + second therapeutic agent |
Combination coverage for MPD. |
| 15 |
(from claim 13) MPD + oral dosing |
Route-specific MPD coverage. |
How broad is the claim language on the CRM1 linkage?
Claim 1 keys off: “a disorder associated with CRM1 activity.” That phrase usually functions as a functional or mechanistic disease linkage rather than requiring a particular genetic marker. For enforceability and litigation posture, this drafting choice tends to produce two practical effects:
- Disease class breadth stays wide at the independent level because it is not limited to a named subset of malignancies.
- Dependent claims then memorialize specific disease buckets (MM, lymphoma, MDS, myeloproliferative disorders), which can be used to argue that the patent’s teachings cover these oncology settings explicitly.
Because the prompt does not include the structural formula or the specification’s definition of “CRM1 activity” (e.g., whether it is nuclear export via XPO1/CRM1, specific assay readouts, or biomarker thresholds), the only defensible conclusion is that the claims are mechanism-linked and then illustrated via explicit oncology examples.
What is the effective “core” of infringement risk?
For a party practicing the invention, claim 1’s infringement trigger is the combination of:
- A subject (patient) with a CRM1-associated disorder; and
- Administration of a pharmaceutical composition comprising:
- the structurally defined CRM1-pathway compound (the specific formula), plus
- a pharmaceutically acceptable carrier; and
- Therapeutically effective amount.
This means the claim is not limited to:
- a specific tumor biomarker,
- a specific dosing schedule,
- a specific drug format (other than dependent oral limitations),
- or a specific combination regimen (unless dependent claim 4 and its downstream dependents are asserted).
How do dependent claims reshape scope (route and combinations)?
Oral dosing coverage (claims 5, 7, 9, 12, 15)
These claims add the limitation that the composition is administered orally. Practically, they create separate infringement exposure for:
- oral dosage forms (tablets, capsules, granules, oral solutions), and
- any oral administration method that falls within the specification’s definition of “orally.”
They do not restrict claim 1’s independent coverage (since claim 1 has no route limitation).
Combination therapy coverage (claims 4, 6, 8, 11, 14)
The dependent combination claims cover “further comprises administering an effective amount of a second therapeutic agent.” This is deliberately nonspecific as to identity, which typically expands the number of potential co-therapies that could still fall within the patent.
It also means a generic “add-on” combination, even if the second agent is a standard-of-care drug, can still satisfy the dependent claim elements as long as all other limitations are met.
Claim structure implications for a patent landscape
Even without the specification text, the claim set signals a patent strategy common in CRM1/nuclear export inhibitor families:
- Independent method claim anchors on the active compound + mechanistic disease association.
- Dependent oncology claims list major hematologic malignancies likely supported by the experimental record.
- Dependent combination and oral claims anticipate real-world commercialization formats (combination regimens and oral dosing).
This affects freedom-to-operate (FTO) differently depending on product profile:
- A parenteral-only product might still map to claim 1 unless claim 1 is successfully limited at enforcement by claim construction or by factual disputes about whether the disorder is “associated with CRM1 activity.”
- An oral combination product increases risk because it can hit both the oral-dependent and the combination-dependent paths.
- A monotherapy oral product hits the oral-dependent claims and claim 1.
Patent landscape: what can be concluded from the claim text alone
The prompt requests “detailed analysis of the scope and claims and patent landscape for US 12,291,508,” but it does not provide the patent’s assignee, filing/publication history, earliest priority date, compound identity (structural formula details), or citations to specific prior art. Without those, an actionable landscape cannot be constructed without guessing key facts (compound family, earlier patents, and claim overlaps).
Under the constraints given, the only accurate landscape statements possible are claim-driven and strategy-driven:
1) This patent is a method-of-treatment around a specific CRM1 compound
The claim set is not directed to:
- a process for making the compound,
- a specific formulation composition beyond “pharmaceutically acceptable carrier,” or
- a specific biomarker assay.
That means competing products that use different actives (not the structurally defined compound) are less likely to be captured by these method claims, but products that share the same structural active are in scope.
2) The landscape risk is highest for “same compound, same indication class”
Because the dependent claims explicitly call out MM, lymphoma, MDS, and myeloproliferative disorders, the highest overlap is with:
- CRM1-pathway agents that target the same mechanistic axis, and
- clinical use in hematologic oncology where those indications are pursued.
3) Combination breadth expands potential design-arounds
The nonspecific “second therapeutic agent” language reduces the ability to avoid infringement by choosing a particular partner therapy. Unless a product can avoid meeting the method elements (e.g., not administering the structurally defined CRM1 compound, or disputing CRM1 association), it can still fall into the combination-dependent claims.
4) Oral dosing dependence creates second-layer exposure
If commercial strategy includes oral dosing, it activates dependent claims (5, 7, 9, 12, 15). A design-around could focus on route, but note: route does not appear in claim 1. Route alone may not eliminate exposure if claim 1 is asserted.
What are the enforceability “pressure points” based on the claim wording?
Pressure point A: “CRM1 activity” and “associated with”
The independent claim uses a functional/association phrase. In enforcement, parties often contest whether:
- the disorder is truly “associated” with CRM1 activity for the patient,
- the administered therapy is actually used to treat a disorder “associated with CRM1 activity,” and
- the therapeutic effect is tied to CRM1 activity rather than unrelated targets.
Because dependent claims list hematologic malignancies, enforcement arguments usually rely on the patent’s disclosure that those indications align with CRM1 biology.
Pressure point B: the “structural formula” identification
The structural formula is the single most specific limitation in claim 1. In litigation, this typically becomes a claim construction and equivalence issue:
- exact structural match versus design-around,
- stereochemistry and substitution pattern, if specified in the full document.
The prompt does not include the formula, so the only firm statement is that the structural formula is the defining element.
Pressure point C: “therapeutically effective amount”
This is standard. Disputes usually focus on dose range, intended use, and whether the regimen is actually therapeutic for the claimed disorder.
Key Takeaways
- US 12,291,508 claim 1 covers a method of treating any disorder “associated with CRM1 activity” by administering a therapeutically effective amount of a pharmaceutical composition containing a structurally defined CRM1-compound and a pharmaceutically acceptable carrier.
- Dependent claims explicitly cover multiple myeloma (2), lymphoma (3), myelodysplastic syndrome (10), and myeloproliferative disorder (13).
- Combination therapy is broadly covered in dependent claims (4, 6, 8, 11, 14) via “a second therapeutic agent” with no identity limitation.
- Oral administration is separately covered (5, 7, 9, 12, 15), creating additional infringement hooks for oral formulations.
- The highest overlap in the patent landscape is with products that use the same structurally defined compound and treat hematologic malignancies where CRM1 activity is implicated, especially in oral combination regimens.
FAQs
1) Does claim 1 require the disorder to be one of the listed cancers?
No. Claim 1 uses “a disorder associated with CRM1 activity.” The listed cancers appear only in dependent claims.
2) Does the patent require oral dosing to be infringed?
No. Oral dosing appears only in dependent claims (5, 7, 9, 12, 15). Claim 1 has no route limitation.
3) Are combination therapies limited to specific second drugs?
No. Dependent claim 4 and its downstream dependents cover “a second therapeutic agent” without naming it.
4) What element is most likely to be targeted in a design-around?
The structurally defined compound of the following structural formula in claim 1.
5) What disease areas are explicitly protected by the dependent claims?
Multiple myeloma, lymphoma, myelodysplastic syndrome, and myeloproliferative disorders.
References
- United States Patent US 12,291,508 (claims as provided in the prompt).
